Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-phase viral decay rates in treatment-naive subjects initiating treatment with raltegravir (RAL) and emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF): A pilot study.

Next Previous
Trial Profile

First-phase viral decay rates in treatment-naive subjects initiating treatment with raltegravir (RAL) and emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF): A pilot study.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 28 Nov 2015 Results from two studies (MK0518-004 and ACTG-A5248) regarding early viral kinetics were published in the AIDS.
  • 07 Nov 2012 Actual initiation date changed from Jun 2008 to May 2008 as reported by ClinicalTrials.gov.
  • 25 Apr 2012 Actual patient number changed from 39 to 40 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top